Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8223458 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 5 Pages |
Abstract
Celecoxib significantly reduced lung toxicity when administered months after LTI when the deleterious effects of radiation were expressed. The schedule-dependent reduction in fatal pneumonitis suggests that celecoxib could be clinically useful by reintroduction of treatment months after completion of radiation therapy. These findings may be important for designing clinical trials using cyclooxygenase-2 inhibitors to treat radiation-induced lung toxicity as a complement to concurrent radiation therapy of lung cancers.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Nancy R. MS, David BS, Zhongxing MD, Luka MD, Howard D. PhD, Kathy A. MS,